Kornimate/medical-research-clean huggingface dataset:
study evaluating anxiety and depression in patients with psoriatic arthritis

Conditions: Psoriatic Arthritis

Summary: this is an epidemiological non-interventional study assessing the prevalence of anxiety and/or depression disorders in patients suffering from psoriatic arthritis (psa) in spain.


Eligibility criteria:
inclusion criteria: * patients both genders over 18 years old * patients with psa diagnosis exclusion criteria: * patients with psa that suffer from other rheumatologic diseases or non-concomitant rheumatologic diseases that the investigator considers not to be appropriate for the study. * patients with any medical or physical condition (cognitive damage or difficulties for understanding) that create difficulties for reading and completing the questionnaires described in the protocol. * patients that in the study period are taking part in another clinical trial.

Keywords: anxiety and depression in patients with psoriatic arthritis
does vitamin d reduce risk of developing type ii dm in high risk individuals

Conditions: Type 2 Diabetes Mellitus

Summary: both vitamin d deficiency and type ii dm/prediabetes are highly prevalent. vitamin d status has been negatively associated with the presence of type ii dm and glycemic control. a cause-effect relationship between vitamin d deficiency and the development of type ii dm has not been established. the investigators plan to conduct a 2 year, double blind, randomized, placebo controlled trial on the effect of vitamin d3 supplement on the incidence of type ii dm in high risk individuals.


Eligibility criteria:
inclusion criteria: * adults living in riyadh area with impaired fasting glucose or/and impaired glucose tolerance (prediabetics) and total 25 oh vitamin d level between 10-30 nmol/l * who consume no more than one serving of milk/day * do not take vitamin supplement * habitually have less than 10 hour of sun exposure per week * don't suffer from granulomatus conditions, liver disease, kidney disease, or diabetes * don't take anticonvulsants, barbiturates, steroids, or antidiabetic medications.

Keywords: prediabetics dm vitamin d
immune response and cytomegalovirus in intensive care unit (icu) patients

Conditions: Cytomegalovirus Infection

Summary: this prospective study evaluate the immune status of patients admitted in icu.cmv remains dormant in the body, but in people with immune deficiency, cmv could reactivate and cause life-threatening pneumonia.

candidates will be screened with medical history and blood tests.then, 2 groups of 20 patients (with or without cmv reactivation) matched for cmv status will be compared for their immune system against cmv.

Eligibility criteria:
inclusion criteria: * age more than 18-year-old * informed consent exclusion criteria: * minors, * pregnant or lactating women, * adults under guardianship, * immunosuppression at the entrance to resuscitation, * aids
citalopram as a posterior cortical protective therapy in parkinson disease

Conditions: Parkinson Disease

Summary: this parkinson disease (pd) trial will test whether 26 months of citalopram, compared to placebo, can alter the build-up of toxic amyloid-beta plaques in the visuospatial cortex of the brain linked to visuospatial cognitive impairment in pd.

this study is a proof-of-concept parkinson disease trial aimed at delaying visuospatial cognitive decline, an important component of parkinson dementia. in parkinson disease, low-range cortical abeta plaque levels associate with serotonin terminal losses. multicenter parkinson disease observational findings show that selective serotonin reuptake inhibitors (ssris) associate with lower dementia conversion risk and different cerebrospinal fluid abeta-42 levels. this study aims to test the hypothesis that citalopram use in parkinson disease will reduce visuospatial cortex abeta plaque accrual, leading to an amelioration of longitudinal visuospatial cognitive decline linked to parkinsonian dementia. the study will test this hypothesis in a randomized placebo-controlled trial of citalopram 20mg daily over 26 months in parkinson disease subjects (age ≥65) without depression (n=58).

Eligibility criteria:
inclusion criteria: * subjects with a parkinson disease (pd) diagnosis based on the united kingdom parkinson's disease society brain bank research center clinical diagnostic criteria * modified hoehn and yahr (hy) scores spanning 2.0 to 3.0 * age 65 years or greater exclusion criteria: * diagnosis of an atypical parkinsonian condition * participants on neuroleptics and participants with a history of use of anti-depressants (including selective serotonin reuptake inhibitors (ssris) and serotonin-norepinephrine reuptake inhibitors (snris), tricyclic antidepressants (tcas), bupropion, st. john's wort or other serotoninergic agents in the year preceding study enrollment * evidence of a large artery stroke or mass lesion on brain imaging * participants with a life threatening comorbid illness * severe claustrophobia precluding pet imaging * inability to participate in research procedures involving ionizing radiation * pregnancy or breastfeeding * participants with active depression as defined by a geriatric depression scale score of \>10 or on the basis of clinical diagnosis by the pi * participants who report active suicidal ideation as defined by an affirmative answer to questions 1 and 2 on the c-ssrs * participants with baseline hy scores \<2.0 or ≥3.0 * participants with a qtc interval on baseline ekg \>0.45 for men or \>0.47 for women * subjects taking certain contraindicated medications at baseline * subjects unable to swallow pills * subjects with a previous history of mania, ongoing hepatic impairment or epilepsy * subjects with a known allergy to citalopram or escitalopram * subjects with substantial cognitive impairment or dementia that would prevent them from providing informed consent * subjects in another ongoing clinical trial * subjects with treatment-naieve parkinson disease

Keywords: serotonin selective serotonin reuptake inhibitor amyloid-beta
mfolfox vs. mfolfiri in advanced or recurrent biliary tract cancer refractory to first line

Conditions: Biliary Cancer Metastatic

Summary: in second line with advanced or recurrent biliary tract cancer refractory to first line gemcitabine plus cisplatin, efficacy of mfolfox vs. mfolfiri will be evaluated at randomized phase 2 trial.

1. brief enrollment criteria * histological confirmed * refractory to first line gemcitabine plus cisplatin * fit for chemotherapy 2. treatment arms a. mfolfox d1 oxaliplatin 100mg/m2 over 2hr leucovorin 100mg/m2 over 2hr 5fu 2400mg/m2 over 46hr every 2 weeks b. mfolfiri d1 irinotecan 150mg/m2 over 2hr leucovorin 100mg/m2 over 2hr 5fu 2400mg/m2 over 46hr every 2 weeks 3. randomization - stratified by tumor site and performance status

Eligibility criteria:
inclusion criteria: * 20 years and older * pathologically confirmed biliary tract cancer (adenocarcinoma) including intrahepatic, extrahepatic, gallbladder, ampulla of vater * initially inoperable or recurrent * ecog 0-2 * as first line chemotherapy, refractory to gemcitabine/cisplatin (at least one cycle applied) * evaluable or measurable lesion * within 1 week, patients who meet below laboratory results (hemoglobin \>9.0 g/dl, neutrophil \>1000/ul, platelet\> 75000/ul, serum creatinine \< unl \* 1.5, ast/alt \< unl\*3, total bilirubin \< unl\*1.5 (available for biliary drainage) * patients who have ability to understand the purpose, benefit and harm for this trial, and the right to withdraw this trial in any time without any disadvantage exclusion criteria: * other cancer history * pregnant or lactating * uncontrolled medical condition such as infection or cardiovascular disease * hypersensitivity to experimental drugs * uncontrolled cns metastasis, psychologic problem

Keywords: second line folfox folfiri
comparative accuracy of three versions of non-invasive hemoglobin monitoring

Conditions: Blood Loss

Summary: there is no study hypothesis. the purpose of this study is to compare the accuracy of the: 1) sphb (radical 7 pulse co-oximetry with sphb™) revf sensor (currently marketed), 2) the sphb revg sensor (a new, limited release version), and 3) the pronto-7 sensor (currently marketed version) in patients undergoing spine surgery.

the purpose of this study is to compare the accuracy of the: 1) sphb revf sensor (currently marketed), 2) the sphb revg sensor (a new, limited release version), and 3) the pronto-7 sensor (currently marketed version) in patients undergoing spine surgery. the results from the three sensors will be compared to a blood hemoglobin level taken intermittently (as a function of the patient's anesthesia care) and analyzed in the ucsf clinical laboratories. this is an observational study.

Eligibility criteria:
inclusion criteria: * ≥ 18 years of age * asa classification 1, 2 or 3 * scheduled to undergo spine surgery exclusion criteria: * pregnant of nursing * in the investigator's judgement would not be suitable for research
paravertebral block for postoperative analgesia in thoracoscopic surgery

Conditions: Pain, Postoperative

Summary: to access the analgesic efficacy of patient controlled thoracic paravertebral analgesia.

the study was carried out on thirty patients who underwent video-assisted thoracic surgery.paravertebral space was identified by loss of resistance technique under video-assisted inside thoracic space before chest close.initiated dose of 0.3ml/kg of bupivacaine 0.125%+fentanyl 2 mcg/ml was administered then continued patient-controlled analgesia with background rate 3ml/h, bolus dose 2ml, lockout interval 10 minutes. postoperative pain was accessed by visual analogue scale at rest and on coughing; monitor the heart rate, blood pressure, respiratory rate, spo2, arterial blood gas and spirometry in three postoperative consecutive days.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists class i to iii risk undergoing elective vats, aged 32-72 years, scheduled for lung resection surgery. exclusion criteria: * patients who refused to participate, less than 18 years of age, asa physical status 3 or more,, allergy to any of the study drugs, patients having any contraindication to placement of pvb, kyphoscoliosis, presence of acute herpes zoster, chronic pain syndrome, chronic analgesic use and psychiatric disease.

Keywords: paravertebral block,pvc,pca
brava: building resilience and attachment in vulnerable adolescents

Conditions: Suicidal Ideation; Suicide and Self-harm

Summary: the prevalence of suicidal ideation (si) among adolescents in north america is high, making it critical to develop evidence-based brief interventions for adolescents with si that target healthy coping skills and relationships. brava is a novel brief group intervention for adolescents with mild to moderate si and their caregivers; youth are taught skills for coping and relating more effectively with others. caregivers learn about adolescent development, effective parenting and the importance of connection. the goal of the randomized controlled trial is to assess the efficacy of a virtually-delivered, brief group intervention for adolescents with mild to moderate si and their caregivers in reducing si.


Eligibility criteria:
inclusion criteria: * adolescents 13 years old to 17.5 years old * mild to moderate suicidal ideation (si without plan or gesture; 1 on the heads-ed) (cappelli, et al., 2012) * interested in study participation * access to an electronic device with internet and email capabilities, and a functioning camera and microphone exclusion criteria: * si with plan or gesture (2 on heads ed; indicated plan or gesture) * comorbid disorders (psychosis, schizophrenia, developmental disabilities, major substance abuse, and severe eating disorders). * referring clinician has identified an externalizing disorder as a primary diagnosis or primary concern (e.g. conduct disorder) * currently participating in regular psychotherapy at least one time per week * currently under children's aid society care * currently in the cheo ed on a form 1 or form 2, or placed on a section 17. * express difficulty with reading and writing

Keywords: adolescent suicidal ideation group therapy crisis
evaluation of the online memory & aging program and online goal management training

Conditions: Aging; Cognitive Decline

Summary: the current study is designed to test the effectiveness of online programs for memory and executive functions in healthy aging. the investigators are testing online adaptations of two cognitive interventions that have been extensively studied, validated, and implemented in clinical settings: the memory \& aging program (map) targets normal memory change in healthy aging, and goal management training (gmt) targets executive functioning deficits in a variety of cognitive and neurological conditions including healthy aging. both programs combine psycho-education, targeted skills training and clinical support to empower participants with knowledge and strategies to harness their cognitive faculties. these programs are being tested against a waitlist control as well as against a commercial/research brain training platform (cambridge brain sciences) in a design comparing performance on memory and executive functioning measures before and after the interventions/controls. the main hypothesis is that map will lead to memory-specific improvements above control conditions, whereas gmt will lead to greater improvements in measures of executive functions relative to controls.


Eligibility criteria:
inclusion criteria: * available to participate in all testing and intervention sessions and access to a computer * computer familiarity * cognitive complaint/concern/frustration exclusion criteria: * health conditions with major effects on cognition, including a current or previous history of stroke, brain surgery, or diagnosed neurological disorder; * dependence in instrumental activities of daily living * cognitive impairment, defined as performance below cutoff for cognitive impairment on a standardized cognitive screening measure, the modified telephone interview for cognitive status (welsh et al., 1993) * affective impairment, defined as performance below cutoff for depression on standardized depression screen, the phq 2/9 (yesavage et al., 1983)

Keywords: healthy aging executive functions memory cognitive training cognitive intervention subjective cognitive impairment
open-label extension study of rosiglitazone xr as adjunctive therapy in subjects with mild-to-moderate alzheimers

Conditions: Alzheimer's Disease

Summary: this is a phase iii, multicenter, open-label extension, single-group study in male and female outpatients with mild-to-moderate alzheimer's disease (ad) who have completed either ava102670 or ava102672. all subjects will receive rosiglitazone extended-release (rsg xr) 4mg once daily for the first 4 weeks of the study followed by 8mg rsg xr as adjunctive therapy to their existing dose of acetylcholinesterase inhibitor. subject participation will last until one of 5 conditions applies. after a 52-week open-label treatment phase, subjects will attend a final follow-up visit 6 weeks after the end of treatment. the primary objective of this study is to evaluate the long-term safety and tolerability of rsg xr in subjects with mild-to-moderate ad who have completed either ava102670 or ava102672. the secondary objective of this study is to explore further the long-term efficacy of rsg xr in terms of cognitive function and overall clinical response as a function of apolipoprotein e (apoe) e4 allele status.


Eligibility criteria:
inclusion criteria: * successful completion of ava102670 or ava102672 without safety or tolerability issues. regular caregiver. exclusion criteria: * congestive heart failure (nyha 1-4), clinically significant peripheral edema, other neurological conditions that might disqualify participation. sae, clinically significant laboratory abnormality or significant cardiovascular event during prior study.

Keywords: cognition alzheimer's disease rosiglitazone extended-release (xr) safety adjunctive therapy brl-049653 tolerability open-label extension
two cycles vs three cycles induction chemotherapy in t1-4n2-3 locally advanced nasopharyngeal carcinoma

Conditions: Locally Advanced Nasopharyngeal Carcinoma

Summary: this trial is a multi-center phase iii clinical trial. the purpose of this trial is to explore whether 2 cycles induction chemotherapy combined with concurrent chemoradiotherapy is not inferior to 3 cycles induction chemotherapy combined with concurrent chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma.


Eligibility criteria:
inclusion criteria: 1. age 18-65 years old; 2. pathologically confirmed non-keratinizing nasopharyngeal carcinoma; 3. stage t3-4n0-1 (according to the uicc/ajcc 8th); 4. no distant metastasis; 5. have not received anti-cancer treatment in the past; 6. ecog (eastern cooperative oncology group of the united states): 0-1; 7. adequate hematologic, hepatic and renal function. exclusion criteria: 1. the purpose of treatment is palliative; 2. diagnosed with other malignant tumors at the same time; 3. malignant tumor history; 4. pregnancy or breastfeeding, or expect to become pregnant during the clinical trial period; 5. combined serious illness.
tunnel vs. caf for the treatment of multiple gingival recessions

Conditions: Gingival Recession

Summary: many studies have compared the tunnel technique and coronally advanced flap in the treatment of single and multiple recessions. however, there is a lack of evidence that compared both techniques in combination with a connective tissue graft, for just multiple adjacent recessions. no technique is clearly superior to another in terms of complete root coverage (crc), mean root coverage (mrc) and the gain of keratinized tissue height (kth) when multiple recession coverage was evaluated. moreover, as a connective tissue graft supposed to offer more stability in terms of complete root coverage in long-term basis, the main question should be aimed at the role of the sub-epithelial connective tissue graft, when it is used in combination with one technique or another. hence, the hypothesis is focused on if the use of a connective tissue graft in combination with a tunnel technique would provide higher clinical outcomes and similar patient-based outcomes than its use in combination with the coronally advanced flap technique.

parallel group, clinical evaluator- and statistician-blinded, randomized clinical trial.

Eligibility criteria:
inclusion criteria: • subjects with a minimum of two adjacent teeth and a maximum of four adjacent teeth with gingival recessions (at least one with a depth ≥ 3 mm) and requiring surgical intervention, without medical contraindications to elective surgery. exclusion criteria: * presence of untreated periodontitis * persistence of uncorrected gingival trauma from tooth brushing * interdental attachment loss greater than 1 mm or furcation involvement in the teeth to be treated * presence of severe tooth malposition, rotation or clinically significant super-eruption * self-reported current smoking * presence of medical contraindications to elective surgery
epidemiology and psychosocial evaluation of inpatient with lung opacity

Conditions: Lung Cancer; Psychological Distress

Summary: lung cancer is one of the leading cause of cancer related death in china.different from patients in the us, chinese patients with lung nodules tend to be less related to smoking, and seem to be more willing to get operation despite of the doctors' suggestion of imaging surveillance. this study is designed to figure out the risk factors for chinese lung cancer patients and evaluate the psychosocial status of inpatients with lung nodules.

smoking is the only determinate risk factor proposed by the nccn（national comprehensive cancer network） clinical practice guidelines for lung cancer screening. however, it has been estimated that over half of chinese female lung cancer patients are non-smokers. thus it might be reasonable to take unique chinese cooking habit and environment pollution into consideration when it comes to the risk factors for lung cancer in chinese people. lung nodules are reported to exist in 25-70% patients who have undergone ldct （low-dose computed tomography）examination. however, the prevalence of malignant nodules is reported to be 1.1-3% by different researchers. even in country with comprehensive medical consulting system and lung nodule management consensus, almost all patients assume their lung nodules to be malignant when detected by ldct for the first time.the investigators noticed nearly 1/3 of the inpatients are determined to get operation despite the surgeons' suggestion of ct surveillance according to the nccn guideline in department of thoracic surgery in peking university people's hospital. as there's no evidence suggesting lung nodules in chinese people have more possibility of malignancy, the investigators would like to know whether those patients who choose to get operation "ahead of the guideline" has higher level of cancer distress, and figure out whether psychosocial factors should be taken into consideration of lung nodules management when living with an indeterminate tumor has added up to patients' negative emotion and reduced their quality of life. the investigators do the survey on the first day of admission during the inpatient education, help patients fill in the questionnaire including personal information, smoking history, medical history, their diet and lifestyle habits, family history of malignant neoplasm, any past or current environmental exposures and psychological status.

Eligibility criteria:
inclusion criteria: * inpatients in department of thoracic surgery in peking university people's hospital and beijing haidian hospital. * tolerant to surgery with accessible pathology outcome. * aged between 18-80. * signed informed consent form. exclusion criteria: * patients who have difficulty in reading and writing. * poor physical status without sufficient respiratory reserve to undergo surgery. * unaccessible for surveillance after surgery. * refuse to take part. * other circumstances which is deemed inappropriate for enrollment by the researchers.
comparative evaluation of osteopathy treatment efficacy in pain support after breast surgery in oncology

Conditions: Breast Cancer

Summary: this is an open, prospective, controlled, randomized, comparative study with 2 arms. the purpose of the study is to assess the efficacy of osteopathy after breast surgery. 80 patients will be enrolled, 40 per arm. patients will be randomized at inclusion and will be followed during one year.


Eligibility criteria:
inclusion criteria: * woman \>= 18 years * pain (median vas \>=3 on the week prior to inclusion) * mastectomy or tumorectomy with axillary dissection \<= 12 months * ps \<=2 * able to write, understand and read french * signed informed consent exclusion criteria: * no pain * immediate breast reconstruction * history of cognitive or psychiatric troubles

Keywords: osteopathy breast cancer pain